Search Within

Hematologic Malignancies, Division of

Formats
  1. Meeting Abstract (6372)
  2. Journal Article (5771)
  3. Review (420)
  4. Editorial (194)
  5. Book Section (188)
  6. Research Letter (179)
  7. Guidelines (88)
  8. Conference Paper (65)
  9. Correspondence (61)
  10. Miscellaneous (18)
  11. Book Whole (9)
Groups
  1. Department of Medicine (13264)
  2. Center for Hematologic Malignancies (10600)
  3. GSK Faculty (4479)
  4. Adult Leukemia (3669)
  5. Bone Marrow Transplant (2847)
  6. Lymphoma (2702)

More Groups

People
  1. Sergio Giralt (1068)
  2. Miguel-Angel Perales (943)
  3. Ross Levine (787)
  4. Andrew Zelenetz (784)
  5. Steven Horwitz (668)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (326)
  2. 2024 (823)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3528)
  2. Journal of Clinical Oncology (1233)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (329)
  5. Haematologica (291)
  6. Bone Marrow Transplantation (239)

More Publications

Publishers
  1. American Society of Hematology (3803)
  2. Elsevier Inc. (1529)
  3. American Society of Clinical Oncology (1288)
  4. Nature Publishing Group (1008)
  5. American Association for Cancer Research (641)
  6. Wiley Blackwell (433)

More Publishers

Results (13365)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immune-MRD status informs tumor-MRD outcome prognostication in multiple myeloma patients on lenalidomide maintenance
    Meeting Abstract

    Firestone, R. S.; Simhal, A. K.; McAvoy, D.; Jurgens, E. M.; GarceĢs, J. J.; Nemirovsky, D.; Derkach, A.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A high-fiber dietary intervention (NUTRIVENTION) in precursor plasma cell disorders improves biomarkers of disease and may delay progression to myeloma
    Meeting Abstract

    Shah, U. A.; Cogrossi, L. L.; Derkach, A.; Castro, F.; Fei, T.; DeWolf, S.; Garces, J. J.; Policastro, A.; Grioni, M.; Sisti, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 1b study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia
    Meeting Abstract

    Gangat, N.; Foran, J. M.; Halpern, A. B.; Rampal, R.; Bose, P.; Hexner, E. O.; Talpaz, M.; Michaelis, L. C.; Islam, P.; Swords, R. T.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of response to hypomethylating agent-based therapy on survival outcomes in the context of baseline clinical-molecular risk and transplant status in patients with myelodysplastic syndromes/neoplasms (MDS): An analysis from the international consortium for MDS (icMDS) validate database
    Meeting Abstract

    Rolles, B.; Bewersdorf, J. P.; Kewan, T.; Blaha, O.; Stempel, J. M.; Lanino, L.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor, showed durable clinical response and sustained hematological improvement in relapsed/refractory myelofibrosis patients
    Meeting Abstract

    El Chaer, F.; Rein, L. A. M.; Yuda, J.; Shimoda, K.; Takami, A.; Ichii, M.; McCloskey, J.; Scandura, J. M.; Iurlo, A.; Bose, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • CDI9-CD28 (RO7443904) combination with glofitamab enhances T-cell proliferation and effector function in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
    Meeting Abstract

    Korfi, K.; Wilson, S.; Jiang, Z.; Christiansen, A.; Krishnan, S.; Jamois, C.; Blank, A.; Epp, A.; Silva, A.; Knuckles, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Cross-talk between leukemic blasts and T cells drives targetable T cell dysfunction in the AML tumor microenvironment
    Meeting Abstract

    DeWolf, S.; Ceglia, N.; Zatzman, M.; Gipson, B.; Elhanati, Y.; Katsamakis, Z.; Lees, H.; Weis, K.; Yepes, G.; Oliveira, B.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Final analysis of the safety and efficacy of venetoclax in combination with Pola-R-CHP for untreated high-risk BCL-2-positive B-cell lymphoma including double/triple hit lymphoma
    Meeting Abstract

    Diefenbach, C. S.; Zelenetz, A. D.; Herbaux, C.; Tani, M.; Houot, R.; Bastos-Oreiro, M.; Tilly, H.; Gastinne, T.; Thieblemont, C.; Leung, W.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Fixed-duration epcoritamab + R-CHOP induces high complete response rates in patients with previously untreated diffuse large B-cell lymphoma with high-risk features: Long-term results from the EPCORE NHL-2 trial
    Meeting Abstract

    Falchi, L.; Offner, F.; de Vos, S.; Brody, J.; Cordoba, R.; Linton, K.; Snauwaert, S.; Clausen, M. R.; Oki, T.; Steele, A. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Predictors of early safety outcomes with axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL)
    Meeting Abstract

    Strouse, C.; Farooq, U.; Shouval, R.; Vallurupalli, A.; Moskop, A.; Jacobson, C. A.; Locke, F.; Baird, J. H.; Strati, P.; Patel, D. A.; more...
    Blood (2024)

    Fulltext@MSK | Save